[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624655":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":35,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"I.M. Sechenov First Moscow State Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"General cohort",null,"500 patients will be structured and entered into an electronic form, which serves as the basis for a clinical decision support system implemented in the form of a decision tree algorithm. This system will be used exclusively for analytical purposes and make it possible to determine the indications for prescribing lipid-lowering therapy, its recommended intensity, and the need to adjust drug doses in accordance with current clinical guidelines",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Peter Chomakhidze, Professor","CONTACT","+79166740369","chomakhidze_p_sh@staff.sechenov.ru",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Fidan Mammadzada, Dr.","+79104443454","fidan.mmzada@gmail.com",[23],{"facility":24,"status":10,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"1 University Hospital","Moscow","119435","Russia","RU",{"type":30,"coordinates":31},"Point",[32,33],37.61781,55.75204,{"lat":33,"lon":32},{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100624655","guideline-adherence-in-dyslipidemia-with-clinical-decision-support-100624655",false,"NCT07412457","Guideline Adherence in Dyslipidemia With Clinical Decision Support","Assessment of Adherence to Clinical Practice Guidelines in Patients With Dyslipidemia Using a Clinical Decision Support System","Inclusion Criteria:\n\n1. Availability of the required amount of patient data for completion of the questionnaire-based system;\n2. Age 18 years or older;\n3. Signed informed consent to participate in the study.\n\nNon-inclusion criteria:\n\n1. Patients with insufficient data to complete the questionnaire;\n2. Refusal to sign informed consent for participation in the study.\n\n   Exclusion Criteria:\n3. Absence of a consensus opinion on the clinical case among two of the three experts.","ALL","18 Years",{"count":47,"type":48},500,"ESTIMATED","OBSERVATIONAL","Objective: To validate the performance of the developed clinical decision support system (CDSS) for participants with lipid metabolism disorders based on a decision tree algorithm.\n\nMaterials and Methods: A clinical decision support system for participants with lipid profile abnormalities will be developed using the Orbeon open-source online form creation platform based on current clinical guidelines.\n\nDuring the CDSS pilot implementation, the electronic medical records (EMRs) of 500 participants from the Institute of Personalized Cardiology of the Biomedical Science and Technology Park at Sechenov University will be analyzed.\n\nRetrospective data on prescribed lipid-lowering therapy extracted from the EHR will be compared with the CDSS recommendations. The accuracy of the decisions will be assessed by three independent experts based on digitized clinical and laboratory patient profiles.\n\nThe primary endpoint of the study will be to determine the accuracy of the system.\n\nResults: This study will result in the development (creation) and pilot application of the CDSS program in participants with dyslipidemia in real clinical practice.\n\nConclusion: The developed CDSS system for dyslipidemia will significantly reduce the time required for clinical decision-making and help avoid errors in the interpretation of patient data.",[52,53,54,55,56],"Dyslipidemia","Coronary Artery Disease","Atherosclerosis of Major Arteries","Cardiovascular Risk","Subclinical Atherosclerosis",[58,59,60,61],"dyslipidemia","atherosclerosis","revascularization","cardiovascular risk","NOT_YET_RECRUITING","2026-02-22",{"date":65,"type":66},"2026-02-24","ACTUAL",{"date":68,"type":48},"2026-04-01",{"date":70,"type":48},"2027-09-30",{"name":5,"class":6},1]